Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Photoreceptors and Visual Pathways

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-damaging laser treatment with electroretinography-based thermal dosimetry activates hormetic heat response in pig retinal pigment epithelium.

Nature communications·2025

Same author

VEGF in Tears as a Biomarker for Exudative Age-Related Macular Degeneration: Molecular Dynamics in a Mouse Model and Human Samples.

International journal of molecular sciences·2025

Same author

Long-Term Natural History of Treatment-Naïve Geographic Atrophy in Age-Related Macular Degeneration.

Translational vision science & technology·2025

Same author

Increasing Incidence of Posterior Uveal Melanoma in Scandinavia 1960-2022: A Tri-National Study.

American journal of ophthalmology·2025

Same author

Metastatic conjunctival melanoma: a multicentre international study.

The British journal of ophthalmology·2024

Same author

Turn-Adopting Peptidomimetic as a Formyl Peptide Receptor-1 Antagonist.

ACS pharmacology & translational science·2024

Search research articles

Related Experiment Video

Updated: Mar 23, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Drusen maculopathy: a risk factor for visual deterioration.

Peep V Algvere¹, Anders Kvanta¹, Stefan Seregard¹

¹Karolinska Institute, St Erik Eye Hospital, Stockholm, Sweden.

Acta Ophthalmologica

|March 25, 2016

Summary

This summary is machine-generated.

Antioxidant supplements, including vitamins C and E, lutein, zeaxanthin, and zinc, can help prevent advanced Age-Related Macular Degeneration (AMD). The Age-Related Eye Disease Study 2 (AREDS 2) showed a 27% risk reduction over 10 years with no adverse events.

Keywords:

age-related eye disease study age-related maculopathy antioxidants drusen lipofuscin pathogenetic features photoelectric effect reactive oxygene species

More Related Videos

Enrichment of Bruch's Membrane from Human Donor Eyes

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

Related Experiment Videos

Last Updated: Mar 23, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Enrichment of Bruch's Membrane from Human Donor Eyes

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

Area of Science:

Ophthalmology
Cell Biology
Genetics

Background:

Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 65, characterized by RPE and photoreceptor cell degeneration in the macula.
Drusen, extracellular deposits on Bruch's membrane, contribute to AMD progression by attracting inflammatory stimuli and impairing RPE function.
Light exposure and genetic factors, including complement system dysregulation (CFH, ARMS2), exacerbate AMD by promoting oxidative stress and drusen formation.

Purpose of the Study:

To investigate the prophylactic effects of antioxidant supplementation on drusen maculopathy and the progression of AMD.
To evaluate the efficacy of specific antioxidant formulations based on the Age-Related Eye Disease Study 2 (AREDS 2) protocol.

Main Methods:

Analysis of data from the Age-Related Eye Disease Study 2 (AREDS 2) involving high-dose antioxidant supplementation.
Long-term follow-up of participants to assess the incidence of advanced AMD and adverse events.

Main Results:

High-dose antioxidant supplementation (vitamins C, E, lutein, zeaxanthin, zinc) significantly reduced the risk of developing advanced AMD by 27% over a 10-year period.
No adverse events were reported in the group receiving antioxidant treatment.
Antioxidants were shown to neutralize reactive oxygen species and decrease lipofuscin accumulation, mitigating mitochondrial dysfunction and cell death.

Conclusions:

Antioxidant supplementation, as defined by the AREDS 2 formulation, is an effective prophylactic treatment for drusen maculopathy, reducing the risk of advanced AMD progression.
The findings support the use of specific antioxidant and mineral combinations for the prevention of AMD, highlighting the role of oxidative stress and inflammation in its pathogenesis.